PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation

Autologous stem cell transplantation (ASCT) remains the standard of care for patients with relapsed/refractory (RR) classical Hodgkin lymphoma (cHL) who respond to salvage chemotherapy. However, relapse after ASCT remains a frequent cause of treatment failure, with poor subsequent prognosis. Because...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Armand, Philippe, Chen, Yi-Bin, Redd, Robert A., Joyce, Robin M., Bsat, Jad, Jeter, Erin, Merryman, Reid W., Coleman, Kimberly C., Dahi, Parastoo B., Nieto, Yago, LaCasce, Ann S., Fisher, David C., Ng, Samuel Y., Odejide, Oreofe O., Freedman, Arnold S., Kim, Austin I., Crombie, Jennifer L., Jacobson, Caron A., Jacobsen, Eric D., Wong, Jeffrey L., Patel, Sanjay S., Ritz, Jerome, Rodig, Scott J., Shipp, Margaret A., Herrera, Alex F.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2019
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6609955/
https://ncbi.nlm.nih.gov/pubmed/30952672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000215
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars